MediciNova to Present Pipeline Progress at 2026 ROTH Conference

MediciNova Inc. ($MNOV) will take center stage at one of the biotech sector's premier investor conferences, with senior leadership scheduled to engage directly with the investment community during the 38th Annual ROTH Conference in Dana Point, California next March. The clinical-stage biopharmaceutical company's participation underscores its commitment to maintaining transparency with institutional investors regarding developments in its drug development pipeline.

Executive Leadership and Conference Details

President and Chief Executive Officer Yuichi Iwaki and Chief Business Officer David H. Crean will represent MediciNova at the conference, scheduled for March 22-24, 2026. Rather than delivering traditional podium presentations, the executives have opted for a more intimate investor engagement strategy, planning to conduct one-on-one meetings and small group sessions with analysts, portfolio managers, and institutional investors throughout the three-day event.

This direct engagement approach reflects a growing trend among clinical-stage biotech companies to cultivate deeper relationships with the investment community. By providing personalized company updates and detailed discussions of their clinical-stage pipeline, MediciNova aims to help investors better understand the company's strategic direction and the potential of its development programs.

Market Context and Industry Backdrop

The ROTH Conference has established itself as a critical gathering for biotech and healthcare innovation investors, attracting hundreds of institutional investors, analysts, and company executives annually. For clinical-stage biopharmaceutical companies like MediciNova, which rely heavily on capital markets for financing drug development, conference participation provides essential visibility and credibility.

MediciNova's pipeline focus reflects broader industry trends:

• Clinical-stage companies increasingly competing for investor capital in a selective funding environment
• Biotech sector emphasis on rare diseases and specialized therapeutic areas
• Growing investor demand for direct access to management teams and detailed pipeline discussions
• Investor preference for companies with differentiated development programs

The ROTH Conference setting—in Dana Point's luxury resort environment—creates an optimal networking venue for substantive discussions between executives and sophisticated healthcare investors who actively manage biotech portfolios. This positioning is particularly important for MediciNova, which operates in the competitive clinical-stage biotech space where many underfunded programs struggle to maintain investor attention.

Investor Implications and Strategic Significance

For shareholders and prospective investors in MediciNova, the company's proactive participation at this premier conference carries several important implications. The decision to engage in direct, substantive investor meetings suggests management confidence in communicating the company's strategic positioning and near-term clinical development milestones.

This investor relations activity occurs within a broader context of the biotech sector facing significant headwinds:

• IPO market challenges for new biotech companies
• Increased scrutiny of clinical trial designs and efficacy endpoints
• Rising development costs requiring larger capital raises
• Competitive pressure from well-funded competitors in key therapeutic areas

For institutional investors evaluating positions in clinical-stage biotechs, direct access to CEO Iwaki and CBO Crean provides opportunities to assess management's technical expertise, strategic vision, and capital efficiency—factors that often determine which clinical-stage programs successfully navigate development to commercialization.

The timing of this conference participation also signals that MediciNova likely has meaningful clinical or operational updates to share with investors, as companies typically use major conference appearances strategically around key value-inflecting events such as clinical trial results, regulatory meetings, or partnership announcements.

Forward Outlook

MediciNova's commitment to direct investor engagement at the 38th Annual ROTH Conference reflects the company's focus on maintaining strong relationships with the capital markets participants who fund early-stage drug development. As clinical-stage biotech companies continue competing for limited capital in an increasingly selective funding environment, the ability to communicate effectively with sophisticated investors remains crucial to long-term success.

Investors interested in MediciNova will have a rare opportunity to access senior leadership directly at the conference, providing a valuable platform to assess the company's clinical pipeline, financial strategy, and competitive positioning within the broader biotech landscape. For the company, effective investor communication at this scale often translates into improved liquidity, stronger institutional shareholder bases, and better access to capital markets when future financing needs arise.